| 13.29 0 (0%) | 11-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Akouos, Inc. is a company dedicated to precise genetic medicine, developing gene therapies with the aim of restoring, enhancing, and safeguarding individuals' natural auditory function. Central to its strategy is an advanced genetic medicine platform, which incorporates a proprietary library of adeno-associated viral vectors and an innovative delivery method. The firm's leading experimental therapy is AK-OTOF, a gene therapy designed to treat hearing impairment caused by mutations in the OTOF gene. Additionally, Akouos is advancing AK-CLRN1 for the auditory symptoms linked to Usher syndrome type 3A (USH3A), and AK-antiVEGF for addressing vestibular schwannoma. The company's comprehensive genetic platform further addresses hearing loss related to genes essential for supporting cell function. Founded in 2016, Akouos, Inc. is headquartered in Boston, Massachusetts.
Thu, 01 Dec 2022
Lilly completes acquisition of Akouos - drugdiscoverytrends.com
Thu, 01 Dec 2022
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases - PR Newswire
Wed, 30 Nov 2022
Lilly and Akouos Announce Expiration of Akouos Tender Offer - PR Newswire
Tue, 18 Oct 2022
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss - PR Newswire
Mon, 19 Sep 2022
Jennifer Anne Wellman Net Worth (2026) - GuruFocus
Mon, 19 Sep 2022
Emmanuel Simons Net Worth (2026) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|